Opinion of the Transparency Council – azathioprinum
At its meeting on 16 August 2022 the Transparency Council adopted Opinion No. 128/20022 on the active substance azathioprinum for the indications: sarcoidosis; interstitial pneumonia – in cases other than those specified in the SmPC, with the exception of idiopathic pulmonary fibrosis; granulomatous lung diseases, in cases other than those specified in the SmPC.
Publication with the minutes of the Transparency Council meeting